Literature DB >> 9151350

An evaluation of community pharmacy records in the development of pharmaceutical care in The Netherlands.

H Rahimtoola1, A Timmers, R Dessing, S Hudson.   

Abstract

An electronic patient database linking prescribes with a Dutch community pharmacy consortium was evaluated in a subset of the population of Noordwijk (11,760 patients out of a total of 25,600). The pharmacy database (a file of 41 disease contra-indications representing a subset of the prescribers' medical diagnosis) was studied in order to assess its value for the accurate discrimination of target patient groups within the community and for support to the pharmaceutical care of individual patients. The aim was to examine the application of the pharmacy records to pharmaceutical care, tested by measuring the accuracy of the pharmacy database to predict the community public health profile; and, more specifically, the accuracy to identify three potential target groups for pharmaceutical care. The records of patients with angina, chronic respiratory disease and diabetes (n = 1116), representing 65% of the total pharmacy morbidity records, were studied in detail and verified by the files and texts of the prescriber's individual patient records. From samples of patients (n = 273) from the three patient groups, the extent and nature of co-morbidity, polypharmacy (drug entities prescribed annually) and drug therapy instability (prescription changes to dose or dose form annually) were characterised. Angina patients showed the most comorbidity, 46% having three or more additional diseases; chronic respiratory disease patients showed most drug therapy instability; and insulin-dependent diabetic patients received most polypharmacy per disease. The pharmacy database predicted the prevalence of 10 of 23 relevant disease categories (representing 51% of the total morbidity on the medical records). However, the prevalences of eight categories were underestimated and of five categories overestimated. Of the three patient groups, 73% of patients appeared on both the pharmacy and the medical database. Of the total co-morbidity recorded for these patients, 68% of records were common to both databases. The database discrepancies (32%) were due to morbidity omitted (12%) and morbidity unverified (10%) on the pharmacy database, together with morbidity omitted from the medical database (10%). The current pharmacy database provides a limited view of morbidity. A strategic approach to pharmaceutical care requires pharmacists and prescribers to verify and share patient information if patient groups and individuals within a group are to be usefully targeted.

Entities:  

Mesh:

Year:  1997        PMID: 9151350     DOI: 10.1023/a:1008608317131

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  13 in total

1.  Indicators for the selection of ambulatory patients who warrant pharmacist monitoring.

Authors:  J A Koecheler; P W Abramowitz; S E Swim; C E Daniels
Journal:  Am J Hosp Pharm       Date:  1989-04

2.  Health promotion priorities for general practice: constructing and using "indicative prevalences".

Authors:  B G Charlton; N Calvert; M White; G P Rye; W Conrad; T van Zwanenberg
Journal:  BMJ       Date:  1994-04-16

Review 3.  Polypharmacy: the cure becomes the disease.

Authors:  C A Colley; L M Lucas
Journal:  J Gen Intern Med       Date:  1993-05       Impact factor: 5.128

4.  Better ways of assessing health needs in primary care.

Authors:  J Shanks; S Kheraj; S Fish
Journal:  BMJ       Date:  1995-02-25

5.  Measuring the ability of clinical pharmacists to effect drug therapy changes in a family practice clinic using prognostic indicators.

Authors:  J E Deady; P W Lepinski; P W Abramowitz
Journal:  Hosp Pharm       Date:  1991-02

6.  Treatment regimen and side effects of treatment measures.

Authors:  W W Busse; R Maisiak; K R Young
Journal:  Am J Respir Crit Care Med       Date:  1994-02       Impact factor: 21.405

7.  Consultation rates and incidence of intercurrent morbidity among patients with chronic disease in general practice.

Authors:  F G Schellevis; E H Van de Lisdonk; J Van der Velden; S H Hoogbergen; J T Van Eijk; C Van Weel
Journal:  Br J Gen Pract       Date:  1994-06       Impact factor: 5.386

Review 8.  Diagnosing obstructive lung disease. Why is differentiating COPD from asthma important?

Authors:  D Subramanian; K K Guntupalli
Journal:  Postgrad Med       Date:  1994-06       Impact factor: 3.840

9.  Information on drug use in the elderly: a comparison of pharmacy, general-practitioner and patient data.

Authors:  E R Heerdink; H G Leufkens; C Koppedraaijer; A Bakker
Journal:  Pharm World Sci       Date:  1995-01-27

10.  Validity of diagnoses of chronic diseases in general practice. The application of diagnostic criteria.

Authors:  F G Schellevis; E van de Lisdonk; J van der Velden; J T van Eijk; C van Weel
Journal:  J Clin Epidemiol       Date:  1993-05       Impact factor: 6.437

View more
  2 in total

1.  Medication assessment tool to detect care issues from routine data: a pilot study in primary care.

Authors:  Tobias Dreischulte; Julienne Johnson; John McAnaw; Marlies Geurts; Han de Gier; Steve Hudson
Journal:  Int J Clin Pharm       Date:  2013-12

2.  The Connected Community Pharmacy: Benefits for Healthcare and Implications for Health Policy.

Authors:  Stephen Goundrey-Smith
Journal:  Front Pharmacol       Date:  2018-11-28       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.